Even as most of its large-cap pharmaceutical peers have struggled to stay above water on the returns front, Zydus Lifesciences has been one of the big outperformers within the sector over the past year with a return of over 30 per cent. The gains have come on the back of multiple triggers such as the scaling up of new product launches in the US market, clearance for its Moraiya (Gujarat) facility and steady performance in the domestic market. Though it has been the top pharma gainer in the 2022-23 financial year (FY23), brokerages continue to maintain their 'buy' stance, given the strong visibility in the US market.
Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
Since two cases against clinical trials started in SC, govt is overly cautious.
Government on Friday assured the Rajya Sabha that essential drugs would not come under the new patent regime and companies manufacturing patented drugs would not be closed down.
Domestic pharma firm inks first-of-its-kind pact.
Western drugmakers, including Pfizer Inc, Novartis AG, Roche Holding AG and Sanofi SA, covet a bigger share of the fast-growing Indian drugs market.
While Pfizer, the world's largest pharmaceutical company, is being criticised for its inability to come up with blockbuster drugs, its global research and development head said the company was working on one of its largest ever assemblage of drugs.
Spurious drugs in large quantities from China are finding their way into India setting off alarm bells in the government which has decided to crackdown on importers who were using forged documents and other means to sneak them in.
The company has entered into an 'in-licencing agreement' with Gilead Sciences Inc to produce and sell, under licence, three new HIV/AIDS drugs which are currently in late stages of clinical development, Ranbaxy Laboratories said.
Indian biotech firm Biocon is developing potential 'blockbuster' drugs for treatment of cancer and diabetes, which could hit the market in two to four years.
Aurobindo Pharma Ltd on Monday said its product Nevirapine tablets 200 mg, has been included by World Health Organisation in its pre-qualification list.
The combined sales of the branded versions of the products in the US is about $3.5 billion.
In an editorial, editor-in-chief Dr Graham Jackson, a UK-based Consultant Cardiologist, has called for greater public awareness of the dangers as well as consequences of the counterfeit drugs market.
He challenged political parties to face the polls with the issue.
At least a dozen global firms, including Roche, Pfizer and Astra Zeneca got a nod from the Drugs Controller General of India to conduct over 50 clinical trials on Indian volunteers this month, official data reveals. The global clinical research outsourcing market is projected to touch $23 billion by 2011, with consultancy firm KPMG estimating that India will corner 15 per cent of this in two years.
Drug major Ranbaxy on Wednesday said it has received approval from the Australian health regulator to market its antipsychotic drug Ozidal Risperidone in that country.
Pharmexcil had recently taken a 25-member delegation to Iran in order to promote pharma trade with the Western Asia nation.
The message of support from Newell's was posted on social media hours before Saturday's home game against Barracas Central in the Argentine league.
In 2009, Ranbaxy had to recall about 4,000 cartons of Sotret Isotretinoin through its US-based subsidiary.
Aurobindo Pharma has received licences from Bristol Myers Squibb Co to market two anti-AIDS drugs in 49 countries.
The World Health Organization (WHO) estimates that more than 30 percent of medicines sold in Africa, Asia, and Latin America are spurious.
The company has received a Civil Investigative Demand from the US Department of Justice, Ranbaxy Laboratories said in a filing to the BSE.
India's Supreme Court in April rejected a patent for Novartis AG's cancer drug Glivec, saying it was an amended version of a known molecule called imatinib, setting the precedent for more such cases in the country.
India's largest drug manufacturer, Ranbaxy Laboratories, had falsified data and test results of medicines manufactured at its Himachal Pradesh facility to obtain marketing approval in the United States, says the US Food and Drug Administration.
Hit by the new drug pricing policy and regulatory interventions, growth rate of the Rs 72,069-crore Indian pharmaceutical market has slowed down to 9.8 per cent in 2013 as compared to 16.6 per cent in 2012, says a report.
Various domestic companies such as Ranbaxy, Wockhardt and Agila Specialities recently came under the US FDA scanner for lapse in manufacturing practices.
Ranbaxy, Dr Reddy's and other Indian drug makers may cut production as overseas buyers, hurt by the credit crunch, defer export orders. The move could also lower the country's drug exports by at least 10 per cent in the year ending March 2010, industry experts say."Many of our members have been intimated by their importers to stop shipments until further notice," said Venkat Jasti, chairman, Pharmaceutical Exports Promotion Council.
Piramal Life Sciences may become the first company to successfully develop a tuberculosis drug whose leads isolated from the living organisms found in ice brought from the Antarctica region. "(Our) scientists have identified additional leads that will help develop drugs to treat tuberculosis and other infections," revealed Swati Piramal, director, Nicholas Piramal.
